Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-05-21

Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating subcutaneous sonelokimab versus placebo for moderate-to-severe hidradenitis suppurativa is currently active but not recruiting, focus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sonelokimab (sonelokimab)

Snippet

Sponsor: MoonLake Immunotherapeutics AG | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: ACTIVE_NOT_RECRUITING